Abstract TH235: Early Adoption of Triple-Combination Single-Pill Antihypertensive Therapy After Formulary Expansion: A Quality Improvement Initiative
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.th235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Vishakha Modak und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Current hypertension guidelines support triple-combination single-pill therapies for patients requiring multiple antihypertensive agents. Compared with dual-combination regimens, triple-combination single-pill therapies (SPCs) achieve greater blood pressure reduction, higher control rates, and reduced pill burden. We evaluated prescribing patterns following increased access to a valsartan-amlodipine-hydrochlorothiazide SPC in a safety-net hospital.
Aim
At baseline, triple-combination SPC therapy was not being used regularly. We aimed to increase provider-reported prescribing of triple-combination SPC at least monthly (≥1 time/month) to >50% of clinicians from November 2025 to January 2026 following formulary expansion.
Methods
As a quality improvement initiative, a valsartan-amlodipine-hydrochlorothiazide SPC was added to the hospital formulary in multiple dose combinations: valsartan 160/320 mg, amlodipine 5/10 mg, and hydrochlorothiazide 12.5/25 mg. Early adoption was assessed via a post-implementation clinician survey. The process measure was clinician awareness of the formulary addition. The primary outcome measure was provider-reported prescribing of triple-combination SPC at least monthly (≥1 time/month). The balancing measure was provider-reported difficulty in titrating individual components of the triple-combination SPC. Clinician perceptions were evaluated using a 5-point Likert-scale survey assessing perceived benefits, barriers, and confidence in prescribing triple-combination therapy.
Results
Forty-one clinicians completed the survey. Seventy-six percent were aware of the formulary addition and reported familiarity with the SPC. Prescribing frequency was: 39% never, 17.1% infrequent (0-1 time/month), 36.6% regular (1-3 times/month), and 7.3% frequent (>3 times/month), with 43.9% reporting at least monthly prescribing. In a clinical vignette of uncontrolled hypertension on dual therapy, 29% selected SPC as the preferred next step. Perceived benefits included improved adherence (88%), reduced pill burden (83%), and increased patient satisfaction (54%). Reported barriers included lack of familiarity (51%) and difficulty titrating individual components (39%). Likert-scale responses showed moderate-to-high confidence in prescribing (mean 3.3/5), with 45% reporting high confidence (4-5).
Conclusions
Following increased access to triple-combination SPC, clinicians demonstrated early adoption, with 43.9% reporting at least monthly prescribing. Lack of familiarity remained the primary barrier. Implementation within a safety-net setting highlights the potential to advance more equitable, guideline-directed hypertension care. Future PDSA cycles will evaluate prescribing patterns and blood pressure control among patients receiving triple-combination therapy.
Zitieren
APA
Modak, V., Satish, V., Szaszdi, D. J. J. R., Faillace, R., & Cartmill, K. (2026). Abstract TH235: Early Adoption of Triple-Combination Single-Pill Antihypertensive Therapy After Formulary Expansion: A Quality Improvement Initiative. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.th235
Vancouver
Modak V, Satish V, Szaszdi DJJR, Faillace R, Cartmill K. Abstract TH235: Early Adoption of Triple-Combination Single-Pill Antihypertensive Therapy After Formulary Expansion: A Quality Improvement Initiative. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.th235
BibTeX
@article{Modak2026,
author = {Modak, Vishakha and Satish, Vikyath and Szaszdi, David Jose Javier Rodriguez and Faillace, Robert and Cartmill, Kimberly},
title = {Abstract TH235: Early Adoption of Triple-Combination Single-Pill Antihypertensive Therapy After Formulary Expansion: A Quality Improvement Initiative},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.th235}
}
EUVIMED